Lowest Net Cost Structure
Every fill is routed to the lowest available net cost option, including generics, biosimilars, and better sourcing channels when clinically appropriate.
Most employer plans overpay for pharmacy through hidden spread pricing, retained rebates, and avoidable brand dispensing. Level Health removes unnecessary markup while making sure members get access to the drugs they need.
A Level Health pharmacy review found significant overspend on specialty and GLP-1 medications. Routing members to lower-cost, clinically appropriate options produced meaningful recurring savings and reduced PMPM pharmacy spend from $191 to $91.
| Medication | Annual Spend | Cost Comparison | Annual Savings | Members |
|---|---|---|---|---|
| HumiraImmunosuppressant / Biologic | $130,000 | $8,000/mo$675/mo | $119,000 | 3 |
| StelaraImmunosuppressant / Biologic | $168,000 | $28,000/mo$10,000/yr | $158,000 | 1 |
| OzempicGLP-1 / Diabetes | $54,700 | $958/mo$300/mo | $27,506 | 11 |
| MounjaroGLP-1 / Diabetes | $54,600 | $1,046/mo$359/mo | $28,854 | 9 |
Every fill is routed to the lowest available net cost option, including generics, biosimilars, and better sourcing channels when clinically appropriate.
The plan pays the true pharmacy cost plus a clear admin fee. There is no invisible claim markup retained by a middle layer.
Manufacturer rebates return to the plan in full. No retained share hidden in fee structures or reclassified line items.
High-cost medications are clinically reviewed for necessity and alternatives so members receive appropriate therapy while plans avoid preventable waste.
Outcome: employer sees a "negotiated" claim but still overpays.
Outcome: $0 spread and clear pharmacy economics.
Traditional PBM models commonly retain a meaningful share of manufacturer rebates. Level Health passes through 100%.
Level Health maintains a high generic dispense rate through active clinical guidance. Brands are used when medically necessary, not because rebate dynamics distort formulary behavior.